Mark Identification

JAQBO

Serial Number

79383436

Filing Date

Sep 14, 2023

Trademark by

JEIL PHARMACEUTICAL CO. LTD

Classification Information

Veterinary pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; proton-pump inhibitor, namely, medicines for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; medicines for the prevention and treatment of gastrointestinal diseases; medicines for the treatment of gastrointestinal diseases; medicines for human purposes, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection; ethical medicinal preparations, namely, medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions, and Zollinger-Ellison syndrome, and combination antibiotic therapy being antibiotics for the treatment of Helicobacter pylori infection

Pharmaceuticals